News

How Investors Are Reacting To DaVita (DVA) Kidney Week Research Push

DaVita reached a settlement of up to US$15,000,000 related to a 2025 ransomware incident and is preparing to showcase seven kidney care studies at ASN Kidney Week 2026, covering dialysis modalities, home-based treatments and patient experience. The combination of legal cleanup around the cyberattack and DaVita’s broad research presence at a major nephrology meeting highlights how cyber risk management and clinical evidence generation both contribute to the company’s operating reality and...

Yahoo·01:10DVA▼−1.3%

Is DaVita (DVA) Still Reasonable After Its 139% Three Year Run?

DaVita has delivered a strong multi year share price run, and with the stock recently closing at US$183.64 the live question is whether that climb is still supported by its earnings power. Over the past 3 years the stock has gained 139.2%, which puts real pressure on the current earnings base to justify where the valuation now sits. DaVita's recent backing of the HHS Kidney Care National Plan and its push into clinical research and value based kidney care can influence how investors view the...

Yahoo·20:13DVA▼−1.3%

DaVita (DVA) Settles Ransomware Case As Kidney Week Research Takes Center Stage

DaVita (NYSE:DVA) agreed to a legal settlement resolving a class action tied to a major 2025 ransomware attack affecting patient data. The 2025 cyber incident involved both personal and clinical information from DaVita kidney care patients, according to settlement filings. DaVita is preparing to present a large slate of kidney care research at the upcoming ASN Kidney Week, highlighting new clinical findings. The ransomware settlement and ASN Kidney Week research push only capture part of...

Yahoo

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know

DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.

Yahoo·17:00DVA▼−1.3%

Outpatient & specialty care stocks Q2 teardown: DaVita (NYSE:DVA) vs the rest

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at DaVita (NYSE:DVA) and its peers.

Yahoo·10:29DVA▼−1.3%

DaVita Earnings Preview: What to Expect

DaVita is set to announce its third-quarter earnings next week, and analysts expect the company's bottom line to expand by double digits.

Yahoo·09:27DVA▼−1.3%

DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice

DaVita today issued the following statement in response to the U.S. Department of Health and Human Services' Kidney Care National Plan and related remarks regarding the future of kidney care:

Yahoo·19:23DVA▼−1.3%

Why DaVita (DVA) Stock Is Nosediving

Shares of dialysis provider DaVita Inc. (NYSE:DVA) fell 7.1% in the afternoon session after Axios reported that the Department of Health and Human Services released a new kidney care plan from the Trump administration.

Yahoo·18:21DVA▼−1.3%

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call

DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.

Yahoo·17:37DVA▼−1.3%

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know

DaVita HealthCare (DVA) closed at $187.25 in the latest trading session, marking a -1.01% move from the prior day.

Yahoo·17:00DVA▼−1.3%

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

DaVita will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years. The research spans emerging approaches to middle molecule clearance, home dialysis and patient experience, underscoring DaVita's role in generating clinical evidence to help advance kidney care.

Yahoo·09:00DVA▼−1.3%

1 Mid-Cap Stock to Target This Week and 2 Facing Headwinds

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Yahoo·03:51

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.

Yahoo·17:00DVA▼−1.3%

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again

DaVita Inc. is rated a Buy with a $220 12-month price target, offering 22% upside from current levels. Read more on DVA stock here.

SeekingAlpha·11:06DVA▼−1.3%

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.

Yahoo·08:50DVA▼−1.3%

DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early

As Hurricane Isaias approaches the Gulf Coast and southeastern United States, DaVita has activated its emergency response plan to help patients continue receiving life-sustaining dialysis care and to support communities preparing for severe weather.

Yahoo·16:00DVA▼−1.3%

DaVita HealthCare (DVA) Laps the Stock Market: Here's Why

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.

Yahoo·17:00DVA▼−1.3%

3 Cash-Producing Stocks with Open Questions

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Yahoo·09:17

DaVita (DVA) Stock May Be Undervalued On Its Earnings Power

DaVita has delivered a strong 87.2% share price gain over the past three years, which naturally raises a question for anyone looking at the stock today. Is the current valuation still grounded in the earnings power of the dialysis provider, or has the share price moved ahead of what the business is generating? A roughly 87.2% return over three years puts real weight on whether DaVita's earnings profile can support the price investors are paying today. The business leans on recurring...

Yahoo·15:07DVA▼−1.3%

This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.

DaVita has made Berkshire Hathaway a lot of money. Is Berkshire likely to hold onto the stock?

Yahoo·06:03DVA▼1.3%

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.

Yahoo·17:00DVA▼−1.3%

Discover which S&P500 stocks are making waves on Thursday.

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

ChartMill·15:05

1 Profitable Stock with Competitive Advantages and 2 That Underwhelm

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Yahoo·04:40

Is DaVita Stock Underperforming the S&P 500?

DaVita has underperformed the S&P 500 index over the past three months. However, Wall Street analysts are moderately optimistic about its prospects.

Yahoo·10:54DVA▼−1.3%

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Benzinga·09:35

AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE

AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of August 31, 2026.

Yahoo·16:06

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.

Yahoo·18:00DVA▼−1.3%

Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You

The investment portfolio of President Donald Trump and Berkshire Hathaway have 17 stocks in common. Here's a look at the list.

Benzinga·08:13

DaVita Community Care Report 2025: Empowering Teammates Through Career Development and Education

Paving Career Paths to Economic Mobility NORTHAMPTON, MA / ACCESS Newswire / September 14, 2026 / Sustainable career growth is about unlocking lasting economic mobility and new opportunities to learn and grow as an individual. In an evolving healthcare landscape, is working to empower teammates through intentional, comprehensive support.

Yahoo·09:40DVA▼−1.3%

DaVita Community Care Report 2025: Our Journey to Net Zero

NORTHAMPTON, MA / ACCESS Newswire / September 10, 2026 / 2025 marked a proud moment for as we met our goal to power 100% of our global operations with renewable energy. We achieved this by securing multiple virtual power purchase agreements in the US and Europe over the past five years - offsetting our global energy consumption with renewable solar and wind power.

Yahoo·08:35DVA▼−1.3%

3 Reasons to Sell DVA and 1 Stock to Buy Instead

DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may have investors wondering how to approach the situation.

Yahoo·10:23DVA▼−1.3%

Commitment to Helping Communities Thrive: DaVita Community Care Report 2025

NORTHAMPTON, MA / ACCESS Newswire / September 8, 2026 / 's care network reaches people in every corner of the U. as well as 14 countries around the world.

Yahoo·09:35DVA▼−1.3%

The Top 5 Analyst Questions From DaVita’s Q2 Earnings Call

DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management attributed this to a mix of operational and industry-specific challenges, including flat treatment volumes and sequential declines in revenue per treatment, primarily due to a less favorable commercial mix and reduced revenue from phosphate binders. CEO Javier Rodriguez emphasized, “Our growth is mainly performance clinical—that expands life,

Yahoo·00:53DVA▼−1.3%

S&P 500 Earnings Are So Good Investors Are Starting to Worry

(Bloomberg) -- The latest reason to worry about the stock market is quite the doozy: Earnings growth has been too strong. Most Read from BloombergPhoebe Gates Knew Phia Shopping App Took Credit for Sales It Didn’t DriveTrump Weighs Call for Capital Gains Tax Cuts as Midterm BoostTata Sons Chairman to Step Down, Deepening Leadership TurmoilFive Takeaways From Zuckerberg’s 6,500-Word Manifesto on AIEpstein Victim Files Cleared for Release Over Maxwell’s ProtestAs the latest reporting season nears

Yahoo·10:45

DaVita Community Care Report 2025: Creating a Culture of Belonging for All

NORTHAMPTON, MA / ACCESS Newswire / August 12, 2026 /Working Together, Working for Better At DaVita, people are the foundation of our community and the driving force behind our pursuit of a healthier tomorrow for all. Rooted in our identity as a community ...

Yahoo·09:35DVA▼−1.3%

DaVita (DVA) Q2 2026 Earnings Call Transcript

Mortality gains drove treatment growth despite payor mix headwinds.

Yahoo·19:58DVA▼−1.3%

Are Wall Street Analysts Bullish on DaVita Stock?

Though DaVita has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Yahoo·10:52DVA▼−1.3%

DaVita (DVA) Stock Still Looks Undervalued Despite A Q2 Earnings Beat

DaVita stock has climbed 69.6% over the past three years. After a recent pullback and a strong value score, the current price still raises questions about how much upside investors are actually paying for. Over the past 3 years, DaVita has returned 69.6%, which puts recent share price weakness in the context of a longer period of strong gains. Support for the valuation can come from expectations that DaVita benefits from growing demand for integrated kidney and metabolic care. Execution...

Yahoo·11:13DVA▼−1.3%

TD Cowen Upgrades DaVita (DVA)

Fintel·20:43DVA▼−1.3%

TD Cowen Upgrades DaVita to Buy, Lowers Price Target to $220

TD Cowen analyst Ryan Langston upgrades DaVita (NYSE:DVA) from Hold to Buy and lowers the price target from $201 to $220.

Benzinga·12:34DVA▼−1.3%